We treated 12 patients with chronic myelogenous leukemia (CML) with a low-intensity preparative regimen followed by allogeneic stem cell transplantation in an attempt to confer a curative graft-versus-leukemia (GVL) effect with minimum morbidity. Seven patients in first chronic phase (CP1) and five in second chronic phase (CP2) (age 15-68 years) received a nonmyeloablative conditioning regimen of fludarabine and cyclophosphamide, followed by a G-CSF-mobilized peripheral blood stem cell (PBSC) transplant from an HLA-identical sibling. Cyclosporine (CsA) was used for graft-versushost disease (GVHD) prophylaxis. Median follow-up was 384 days. Neutrophil recovery occurred at a median of 12 days. There was no transplant-related mortality. Of the seven CP1 patients transplanted, seven achieved a stable molecular remission; two with no post-transplant intervention, three after donor lymphocytes, imatinib and interferon, and two after a myeloablative stem cell transplant. Four of five CP2 patients died in blast crisis and one survived in molecular remission. Of the 12 patients with durable engraftment, six had Grades II-IV acute GVHD; six had limited chronic GVHD. These results suggest that cytoreduction is required to optimize the curative effect of allogeneic stem cell transplantation for CML. Bone Marrow Transplantation (2003) 32, 897-901. doi:10.1038/sj.bmt.1704231 Keywords: chronic myelogenous leukemia; graft-versusleukemia; nonmyeloablative stem cell transplantation Allogeneic stem cell transplantation (SCT) can produce durable molecular cures of chronic myelogenous leukemia (CML). This antileukemia effect of SCT has been attributed to two factors: the myeloablative conditioning regimen and an allogeneic graft-versus-leukemia (GVL) effect.
leukemia; nonmyeloablative stem cell transplantation Allogeneic stem cell transplantation (SCT) can produce durable molecular cures of chronic myelogenous leukemia (CML). This antileukemia effect of SCT has been attributed to two factors: the myeloablative conditioning regimen and an allogeneic graft-versus-leukemia (GVL) effect. 1 The GVL effect is particularly strong in CML as evidenced by the widely reproduced ability of transfusions of donor lymphocytes to produce durable molecular remissions in patients relapsing after SCT. 2, 3 The therapeutic benefit of allogeneic SCT is mitigated by regimenrelated toxicity and consequent transplant-related mortality (TRM) from high-dose myeloablative treatment. In CML, for example, TRM of 10-20% have been reported. 4, 5 In an attempt to reduce TRM, lower intensity preparative regimens are being increasingly explored for a variety of transplant indications. [6] [7] [8] [9] 10 We previously reported the characteristics of a low-intensity preparative SCT regimen, which does not myeloablate the recipient and has low toxicity. [11] [12] [13] We used this transplant protocol to treat a series of CML patients who had a matched sibling donor. The aim of the study was to determine whether a reduced intensity transplant regimen could achieve a durable molecular remission in CML by a GVL effect, while reducing TRM. Here, we report the results of a cyclophosphamide-fludarabine-based preparative regimen followed by allogeneic peripheral blood stem cell (PBSC) transplantation in 12 patients.
Patients and methods

Patients studied
Patients with chronic phase CML referred for consideration for a stem cell transplant between 1997 and 2000 were treated with a nonmyeloablative transplant if they were o55 years (n ¼ 6), had comorbidities that could increase TRM (n ¼ 1), or if they chose the lower intensity transplant, after full explanation and discussion of the differences between nonmyeloablative and myeloablative stem cell transplantation (n ¼ 5). In total, 12 patients gave written informed consent to participate on protocols 98-H-202, 99-H-050, and 00-H-001 approved by the institutional review board of the National Heart, Lung and Blood Institute. The diagnosis of CML was confirmed in all patients by karyotyping for the Philadelphia positive (Ph þ ) chromosome. All 12 patients received a PBSC allograft from an HLA-identical sibling donor.
Transplant regimen
The preparative regimen consisted of cyclophosphamide 60 mg/kg i.v. on days À7 and À6 before transplant, followed by fludarabine 25 mg/m 2 daily on days À5 to À1. , and 5 Â 10 7 CD3 cells/kg recipient weight), with weekly assessment of chimerism, until complete T-cell chimerism, GVHD, or molecular remission of CML occurred. Also, patients with CML persisting even after the withdrawal of CsA, who did not have grade III or IV GVHD, received up to three infusions of donor lymphocytes given monthly in escalating doses. Patients who had no response to treatment with donor lymphocytes and those who were not candidates for additional lymphocyte infusions received low-dose subcutaneous interferon-alpha, interleukin-2 or oral imatinib to enhance a GVL effect.
Stem cell donation
Donors gave written informed consent to undergo stem cell mobilization and leukapheresis. Stem cell donors received 10 mg/kg/SC GCSF daily for 5-6 days. PBSC were collected by leukapheresis on day 5, and again on days 6 and 7 if necessary, to obtain a target dose of more than 5 Â 10 6 CD34 cells/kg recipient weight.
Measurement of chimerism and residual leukemia
Patients with morphologically normal bone marrow and peripheral blood counts within normal limits were considered to be in hematological remission from CML. Donor-recipient chimerism was assessed by PCR of mini (VNTR) or micro (STR) satellite regions polymorphic between patient and donor. Residual disease was monitored by PCR for BCR-ABL on peripheral blood and by karyotyping and fluorescent in situ hybridization (FISH) on bone marrow aspirates. For chimerism assessment, DNA was extracted from purified samples of neutrophils (CD15) and T cells (CD3 þ ) using magnetic beads coated with the relevant antibody. Varying ratios of donor and patient pretransplant DNA were used to estimate the degree of chimerism.
14 FISH was performed with probes for chromosome X, Y, and BCR-ABL (Vysis Inc., Downers Grove, IL, USA). Slides were denatured by immersion in formamide/20 Â SSC solution for 5 min at 731C followed by several washes in 70, 85, and 100% ethanol at room temperature for 1 min each time. Probes were denatured as above and applied to the cells on the slides to hybridize at 421C overnight. After hybridization, the slides were washed in prewarmed 0.4xSSC at 731C for 2 min, and 2xSSC/0.1% NP-40 at room temperature for 1 min. The slides were allowed to dry in the dark and counterstained with DAPII for enumeration using a fluorescence microscope. The percentage of positive staining was based on 200 cells scored.
Results
Patient characteristics
A total of 12 CML patients (nine male, three female), median age 43 (range 15-68 years), were studied (Table 1) . Eight were in first chronic phase (CP1) and five in second chronic phase (CP2) at the time of transplant. Median follow-up was 384 days (34-843). Prior treatment is shown in Table 1 .
Engraftment
Neutrophil recovery occurred within an average of 11 days. [8] [9] [10] [11] [12] [13] [14] In all, 10 patients had sustained donor engraftment. T-cell engraftment was more rapid than myeloid engraftment, with all 12 patients having X90% donor T-cell chimerism by day þ 30. In contrast, myeloid chimerism was typically mixed (donor and recipient) for (Table 2) . One patient relapsed within a month of transplant.
Regimen-related toxicity
Patients tolerated the transplant regimen well. Conditioning-related mucositis, cardiac toxicity, and veno-occlusive disease were not observed. No documented bacterial infections occurred within 100 days of transplantation. CMV reactivation occurred in five patients who were seropositive for CMV and was successfully treated with i.v. ganciclovir.
GVHD
The main complication post transplant was GVHD: Of 11 patients evaluable for GVHD (one patient relapsed within a month of transplant), six had Grades II-IV acute GVHD (five had Grade I/II, one Grade III, two Grade IV), which resolved following treatment with methyl-prednisolone. Limited chronic GVHD occurred in five (Table 3) . Serum creatinine elevations were observed in four; all but one was reversible after tapering CsA. One patient developed transient nephrotic syndrome post transplant complicated by a pulmonary embolism necessitating long-term anticoagulation.
Control of leukemia
Immediately after transplant, all patients recovered leukemic hematopoiesis as evidenced by high leukocyte counts, bone marrow presence of the Ph chromosome and t(9; 22) by FISH, and persisting recipient myeloid chimerism. Three patients (two transplanted in CP1 (patients 1 and 2) and one transplanted in CP2 following ALL blast crisis (patient 9)) showed a GVL response 3-4 months post transplant, characterized by a fall in blood counts, the complete replacement of recipient myeloid cells by those of the donor, and loss of Ph þ chromosomes in the marrow. In the following months they all achieved molecular remission. Two had sustained molecular remissions 36 and 48 months post transplant (patients 6 and 7). The third had a brief molecular relapse 2 years after being in remission, but reentered remission following immunosuppression withdrawal and remains in molecular remission more than 4 years post transplant (patient 9). Five of the seven patients transplanted in first CP had persisting hematological disease. Three achieved a molecular remission after combinations of DLI with imatinib and addition of interferon-a in one. Two patients progressed to accelerated phase, both of whom achieved molecular remission after myeloablation with cyclophosphamide 120 mg/kg and 13.6 cGy of total body irradiation (TBI) followed by second transplant from the same donor. Four of the five patients transplanted with more advanced CML died of disease progression despite attempts to treat the relapse with DLI, imatinib, or a second transplant in one. A summary of the PCR data and additional treatments is shown in Figure 1 .
Discussion
The use of reduced-intensity preparative regimens to treat patients with hematological malignancies has been driven by a need to improve the chances of survival from allogeneic SCT by reducing the toxicity of the regimen. Initially applied to patients considered at high risk because of age or comorbidity, we widened the inclusion criteria to offer low-intensity transplants to younger patients with CML otherwise eligible for standard transplant regimens. This was justified by the o5% TRM in patients less than 48 years receiving this fludarabine cyclophosphamideconditioning regimen and the possibility of preserving fertility. Both TBI-based and nonmyeloablative transplant approaches were available at our institution. Patients who chose to have a nonmyeloablative transplant did so because of its lower risk of morbidity and mortality, despite a less certain antileukemia effect. Of the 12 patients transplanted, five with CML in first CP were under 40 years of age with no comorbidities. Overall, the low morbidity and mortality of this fludarabine-cyclophosphamide-based regimen was confirmed -no patient died of transplant-related complications. As previously described, this protocol was associated with rapid recovery from neutropenia, earlier reconstitution of immunity, and less toxicity when compared to standard myeloablative regimens. 11 The major complication was acute GVHD, which resolved in all patients following immunosuppressive therapy. Chimerism analysis and detection of persisting CML by karyotyping, FISH and PCR confirmed that this combination of fludarabine and cyclophosphamide is indeed nonmyeloablative. The pattern of delayed CML regression following transplantation was consistent with an antileukemia effect from the engrafted donor immune system rather than the consequence of the preparative regimen. The stable molecular remissions produced in the three patients using this approach were proof of the principle that a GVL effect is sufficient in some patients to eradicate CML. Patients who failed to achieve a durable remission without adjuvant therapy included patients in first chonic remission without indicators of progressive disease, as well as those in whom a myeloablative transplant was less likely to be successful, that is, those in second remission, or those with a high tumor burden indicated by splenomegaly or significant leukocytosis. However, it was disappointing that the majority of patients failed to enter remission after transplant and required further treatment for disease eradication. In addition, three developed disease relapse before the onset of GVHD; in one, the CML cells appeared to replace the normal donor marrow as evidenced by our inability to identify donor myeloid cells by mini-satellite PCR. In this regard, it is notable that myeloablation followed by a transplant from the same donor achieved a molecular remission in 2/2 patients, and that DLI in combination with imatinib was effective at achieving molecular cures in three. As expected, patients with more advanced CML fared less well than those transplanted in CP1. This would be expected, as the GVL effects are far less effective in eradicating disease in patients in whom the tumor is rapidly proliferating. 15 In this regard other 'non-myeloablative protocols' using a more aggressive approach adding more chemotherapy or radiation were more effective without the addition of adjuvant treatments in producing durable responses. 8, 16 Four patients died from disease progression in blast crisis despite imatinib or a second transplant in one.
While these results confirm that this cyclophosphamide/ fludarabine-based nonmyeloablative transplant can reliably engraft a competent donor immune system (as evidenced by full T-cell chimerism, low incidence of CMV reactivity, Nonmyeloablative allografts for CML and occurrence of GVHD), we were struck by the failure of GVL despite significant GVHD following transplant or DLI. This contrasted with the success of salvage treatment with a myeloablative transplant, or with the use of imatinib in conjunction with DLI. The results suggest that a high leukemia burden post transplant contributed to the inability of the immune system to eradicate leukemia. In contrast to our experience with fludarabine and cyclophosphamide, nonmyeloablative transplants using TBI or busulfan produce prompt replacement of recipient myelopoiesis with that of the donor. Furthermore, such regimens result in better disease control in CML; Slavin et al 17 report 21/24 molecular remissions. The Seattle group reported success in five of nine patients transplanted in CP using low-dose radiation (200 cGy given as a single fraction). 8 Our findings have important implications for designing low-intensity preparative regimens for treatment of CML. Better results are likely to be achieved with preparative regimens that reduce the stem cell compartment, such as low-dose TBI or busulfan. Likewise, one might speculate that better disease control while retaining low morbidity and mortality could be achieved by combining fludarabine and cyclophosphamide with imatinib as an approach to leukemia cytoreduction.
